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Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania (NTD) endemic in
98 countries. Although some drugs are available, current treatments deal with issues such as toxicity, low
efﬁcacy, and emergence of resistance. Therefore, there is an urgent need to identify new targets for the
development of new antileishmanial drugs. Protein kinases (PKs), which play an essential role in many
biological processes, have become potential drug targets for many parasitic diseases. A reﬁned bioinformat-
ics pipeline was applied in order to deﬁne and compare the kinomes of L. infantum and L. braziliensis, spe-
cies that cause cutaneous and visceral manifestations of leishmaniasis in the Americas, the latter being
potentially fatal if untreated. Respectively, 224 and 221 PKs were identiﬁed in L. infantum and L. braziliensis
overall. Almost all unclassiﬁed eukaryotic PKs were assigned to six of nine major kinase groups and, conse-
quently, most have been classiﬁed into family and subfamily. Furthermore, revealing the kinomes for both
Leishmania species allowed for the prioritization of potential drug targets that could be explored for discov-
ering new drugs against leishmaniasis. Finally, we used a drug repurposing approach and prioritized seven
approved drugs and investigational compounds to be experimentally tested against Leishmania. Trametinib
and NMS-1286937 inhibited the growth of L. infantum and L. braziliensis promastigotes and amastigotes
and therefore might be good candidates for the drug repurposing pipeline.
© 2019 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Leishmaniasis is a parasitic disease caused by the etiologic agent
Leishmania spp. The parasites are transmitted to humans through
the bite of infected phlebotomine sandﬂies from the Lutzomyia and
Phlebotomus genera. [1]. The disease is clinically classiﬁed based on its
manifestations as Visceral Leishmaniasis (VL) and Cutaneous Leishman-
iasis (CL) and on the Leishmania species parasitizing the host. Two im-
portant human pathogen species are Leishmania infantum, which cause
New World and Old World VL, and Leishmania braziliensis, which is
among the species causing CL in the Americas [2–4].
The countries most affected by leishmaniasis are in Africa, Asia,
and Latin America. It is estimated that about 0.2 to 0.4 million new
cases of VL and 0.7 to 1.2 million new cases of CL appear each year.
Yearly, there are around 20,000–40,000 deaths in the world related
to the disease [5,6]. The current treatment of VL and CL rely on pen-
tavalent antimonials - amphotericin B, paromicine, pentamidine,
and miltefosine - which have issues with toxicity and administra-
tion. In addition, their effectiveness is compromised due to the
emergence of resistant strains. Hence, there is a need for developing
new drugs against leishmaniasis [7,8].
Protein kinases are among the largest protein families coded in the
genome of most organisms, constituting ~2% of the diversity of eukary-
otic genomes [9]. They are mediators of many regulatory, signal trans-
duction, and cell development pathways [10]. Thus, a considerable
research effort to select molecular targets for new compounds is cen-
tered around protein kinases [11–13]. Protein kinases exercise their
role by phosphorylating other molecules [13]. Eukaryotic kinases
(ePK) have a very conserved domain composed of 11 subdomains and
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their tridimensional structure has aN-terminal lobewith an antiparallel
β-sheet and a C-terminal lobewithα-helices [14]. Proteins that transfer
phosphates from ATP to other biomolecules and do not have the eu-
karyotic kinase domain are termed atypical protein kinases (aPK) and
protein kinase like (PKL) [15].
ePKs are classiﬁed according to the amino acid they phosphorylate:
serine/threonine protein kinases or tyrosine protein kinases [16]. They
are further classiﬁed into 9 groups, based on their sequence similarity,
according to theManning classiﬁcation [14]: (i) theAGC group – protein
kinases A, G, and C; (ii) CAMK group – Ca+/CAM-dependent kinases;
(iii) CMGC group – CDK, MAPK, GSK3, and CLK; (iv) CK1 – casein kinase
1; (v) STE group – homologs of yeast sterile 7, 11, and 20; (vi) RGC
group – receptor guanylate cyclases (vii) TK group – tyrosine kinase;
(viii) TKL group – tyrosine kinase-like; and (ix) “Other” group – several
kinase families that do not ﬁt within any of the other main kinase
groups [15–17].
Given that (a) protein kinases have essential roles in the cell [10];
many human kinase inhibitors have been successfully applied especially
in cancer therapy [18]; and that (b) kinases have conserved structures
and functions [12], revealing the L. infantum and L. brazilienis kinomes
may accelerate the drug discovery process for leishmaniasis. Here,
we have elucidated for the ﬁrst time the kinomes of L. infantum and
L. braziliensis, species that cause visceral and cutaneous leishmaniasis,
respectively, in the Americas.We developed and applied a robust bioin-
formatics pipeline that enabled us to classifymost of the protein kinases
at a subfamily level. We also applied a drug repurposing workﬂow that
prioritized novel protein kinases that are essential for the parasite's
survival or are central in a protein interaction network. Moreover, we
selected and experimentally evaluated some kinase inhibitors that
might inhibit some of these targets. The general workﬂow of this
study is presented in Fig. 1.
2. Material and Methods
2.1. Deﬁnition and Prediction of L. infantum and L. braziliensis Kinomes
We performed a proteome-wide analysis of PKs of the species
L. infantum and L. braziliensis using amodiﬁed and reﬁned bioinformatics
pipeline described elsewhere [19]. Brieﬂy, the proteomes of L. infantum
and L. braziliensiswere inputted into the program Kinannote v.1.0 [20].
The kinases were classiﬁed into groups, families, and, ultimately, sub-
families. Proteins with partial classiﬁcation or that were unclassiﬁed
were kept for further manual curation. The L. major kinome [21] was
used as a reference to further classify the unclassiﬁed and partially clas-
siﬁed kinases, to improve their classiﬁcation, and to ﬁnd proteins that
were not detected by Kinannote. In order to precisely compare L.
major, L. infantum, and L. braziliensis kinomes, we predicted the ortholo-
gous sequences from the proteomes of the 3 species using the program
OrthoMcl v.2.0.9 [22]. InterproScan v.5.18 (https://www.ebi.ac.uk/
interpro/search/sequence-search)was used to elucidate and localize ki-
nase domains of the classiﬁed proteins. We also constructed HMM pro-
ﬁles for individual kinase groups based on closely related organisms'
kinase classiﬁcations, then searched these proﬁles through the prote-
omes of L. infantum and L. braziliensis. The HMM proﬁle construction
and searchwas done based on the catalytic domain sequence of individ-
ual kinase groups of L. major, T. brucei, and T. cruzi protein kinases using
HMMer v. 3.1b2 (http://hmmer.org/) software.
2.2. Phylogenetic Tree Construction
In order to study the relationships within the L. infantum kinases
from each group, multiple phylogenetic trees were constructed.
For each group, only the catalytic domains were kept for automatic
multiple sequence alignment (MSA) using MAFFT v. 7.215 [23]
in most accurate mode (L-INS-i; parameters –localpair –maxiterate
1000). Next, the alignments were improved using the –reﬁne switch
in MUSCLE v. 3.8.31 [24]. Biopython scripts [25] were used to
convert between the MSA formats generated by the distinct tools.
ProtTest3 v. 3.4.2 was used to select the best-ﬁt model of amino
acid replacement according to the Akaike information criterionmea-
sure [26]. PhyML v. 20,131,022 [27] was used to infer maximum like-
lihood trees with 1000 bootstrap replicates using the amino acid
substitution model chosen in the previous step. FigTree v. 1.4.3
(available at http://tree.bio.ed.ac.uk/software/ﬁgtree/) was used to
perform tree visualization, editing, and export.
Fig. 1. Bioinformatics pipeline used to deﬁne and characterize L. infantum and L. braziliensis kinomes, prioritize kinase targets and select drugs to target Leishmania protein kinases.
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2.3. Functional Annotation
The ﬁnal list of classiﬁed protein kinases was functionally annotated
by searching the KEGG BRITE (http://www.kegg.jp/blastkoala/) and
Gene Ontology (http://www.geneontology.org/) databases; a consen-
sus classiﬁcation was manually annotated.
2.4. Comparison of L. infantum, L. braziliensis and Homo sapiens Kinomes
The comparison of the 3 kinomes was done using the software
OrthoVenn (http://probes.pw.usda.gov/OrthoVenn/) to infer which
proteins cluster together and to ﬁnd kinases present in both Leish-
mania species and absent in humans. Pairwise alignment of the
kinomes was performed using the BLASTP algorithm v. 2.2.24 [28]
locally at default parameters.
2.5. Drug Target Prediction and Prioritization
In order to select potential drug targets among the kinomes, we per-
formed an essentiality search by selecting L. infantum proteins homolo-
gous (BLASTP; e-value ≤10−30) to T. brucei kinases with lethal siRNA
phenotypes – found at Tritrypdb (http://tritrypdb.org/tritrypdb/).
A complementary target prioritization approachwas performed by con-
structing a protein network interaction of kinase proteins through
STRING [29] v. 10.0 (https://string-db.org/)web server and the resulting
network was analyzed from a graph-theoretic perspective. Topological
measures of centrality in this network were calculated using the
CytoNCA Cytoscape v.3.3.0 plugin [30].
2.6. Compound Selection for Experimental Evaluation
The FASTA sequences of each prioritized target were used to interro-
gate two different publicly available databases that provide detailed
information on drugs and their targets: DrugBank [31] and kinase
SARfari (https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari/). The
search strategy was based on the principle of homology, where each
query (L. infantum targets) was compared for matches to known drug
targets contained in each database. We set a strict threshold on the
E-value ≤10−30 to consider the target as acceptable andwe only consid-
ered approved drugs or compounds in clinical trials for this search. We
also searched for “druggability” of the targets in kinase SARfari. Then, a
list of drugs/compounds and their possible targets was compiled. A lit-
erature search was carried out using the PubMed and PubChem data-
bases and SciFinder engines to identify which of the compounds
related to the selected targets have not been evaluated against Leish-
mania species. The details of the search were in the format: (“drug
name” [MeSH Terms] OR “drug name” [All Fields]) AND (“Leishmania”
[MeSH Terms] OR “Leishmania” [All Fields]). After applying the litera-
ture search ﬁlter, the antileishmanial activity of these compounds
were predicted using an in-house QSAR phenotypic model for L.
infantum. The compounds predicted to be active by the QSAR model
were purchased for in vitro experimental evaluation.
2.7. In vitro Evaluation of Selected Compounds in Leishmania spp
Fresh aliquots from 10mMDMSO (Sigma-Aldrich)-diluted stock so-
lutions of seven kinase inhibitors (Selumetinib, Refametinib, MEK162,
MLN8054, RG1530, NMS-1286937 and Trametinib; purchased from
MedChemExpress)were prepared and tested against L. (L.) amazonensis
(MHOM/BR/PH8), L. (L.) infantum (MHOM/BR/1972/LD) and L. (V.)
braziliensis (MHOM/BR/94/H3227) promastigotes as described else-
where [32]. Compounds with good antileishmanial activity were tested
against L. (L.) infantum and L. (V.) braziliensis intracellular amastigotes.
Parasites were maintained at 26 °C in medium 199 (Sigma-Aldrich)
as previously described [33]. To perform the promastigote assays, ap-
proximately 5 × 106 logarithmic-phase promastigotes were incubated
with increasing concentrations of each kinase inhibitor (1, 5, 10, 20,
75, and 100 μM) in triplicates. Viabilitywas assessed by theMTTmethod
and 50% of effective concentrations (EC50%) were determined by sig-
moid regression analysis using Prism 5.0a (GraphPad Software. Inc.).
To perform the amastigote assays, 4 × 105 BALB/c bone marrow
derived macrophages (BMDM) were obtained [34] and infected with
L. (L.) infantum and L. (V.) braziliensis stationary-phase promastigotes
(at a ratio of 10 parasites; 1 BMDM) for 24 h in 24 well plates and kept
at 37 °C and 34 °C, respectively. The protocol was approved by the Ani-
mal Experimentation Ethics Committee (CEUA-UNICAMP #4535-1/
2017). Established infections were incubated with 10, 15 and 30 μM of
NMS-1286937 and Trametinib. Parasite burdenwas assessed by counti-
ng intracellular amastigotes in at least 200 BMDM per coverslip. Each
assay was performed in triplicates and the reduction in amastigote
number was compared to the untreated infection group (100%).
3. Results
3.1. Deﬁnition and Prediction of L. infantum and L. braziliensis Kinomes
3.1.1. L. infantum Kinome
We developed and applied an integrative bioinformatics pipeline
(Fig. 1) that allowed us to identify 197 protein kinases in the L. infantum
proteome. From these original 197, 40 kinaseswere assigned to subfam-
ilies, 109 to families, 18 to groups, and 30 remained unclassiﬁed. After
manual curation and improvement of this draft kinome (see Methods
Section), we obtained a total of 224 kinases (196 ePKs, 28 PKLs/aPKs),
of which 157 were assigned to subfamilies, 64 to families, three to
groups, and only one remained unclassiﬁed (Table 1).
A total of 195 ePKs were identiﬁed in L. infantum proteome. There
were representatives of six kinase groups (Table 2), amongwhich 12 ki-
nases were classiﬁed into the following families of AGC group: protein
kinase B (AKT, n = 1); nuclear DBF2-related kinases (NDR, n = 1);
phosphoinositide dependent protein kinase 1 (PDK1, n=3); protein ki-
nase A (PKA, n = 3); and ribosomal S6 kinase (RSK, n = 2). Two AGC
kinases were not assigned to any family.
Twenty-three kinases were classiﬁed into the following families
of CAMK group: CAMK family 1 (CAMK1, n = 6); calcium/calmodulin
protein kinase-like (CAMKL, n = 11); CAMK-Unique (n= 4); and the
calcium-dependent protein kinase (CDPK, n= 2). The group CK1 had
7 members, of which 6 were identiﬁed as cell kinase 1 family (CK1)
and one was from the tau tubulin kinase family (TTBK).The CMGC
group is one of themost represented in L. infantum kinome,with 50 pro-
tein kinases classiﬁed in the following families: cyclin-dependent pro-
tein kinase (CDK, n= 14); cell kinase 2 (CK2, n= 2); CDC-like kinase
(CLK, n= 4) dual-speciﬁcity tyrosine-regulated kinase (DYRK, n= 9);
glycogen synthase kinase 3 (GSK, n= 2); mitogen-activated protein ki-
nase (MAPK, n= 13); resistance to complement killing (RCK, n= 3);
and SR protein kinase (SRPK, n = 3). Forty-one PKs were assigned to
the following families of STE group: MAP kinase kinase kinase genes,
homologous to yeast Ste. 11 (STE11, n=31); MAP kinase kinase kinase
kinase genes, homologous to yeast Ste20 (STE20, n=2);MAP kinase ki-
nase genes, homologous to yeast Ste. 7 (STE7, n= 7); and STE-Unique
(n = 1). The group “Other” contains several kinase families that do
not ﬁt within any of themain kinase groups. Therewere 62 kinases clas-
siﬁed into the families of this group: aurora kinase family (AUR, n=3);
Table 1
Leishmania infantum and L. braziliensis kinome classiﬁcation before and after curation. The
classiﬁcation into families and subfamilies was improved and most kinases that were not
classiﬁed in the initial steps could be further identiﬁed by manual curation.
Group Family Subfamily Unclassiﬁed
L. infantum (Draft) 18 109 40 30
L. infantum (Final) 2 64 157 1
L. braziliensis (Draft) 22 114 31 28
L. braziliensis (Final) 3 61 155 2
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Bud 32 (n = 1); calcium/calmodulin-regulated kinase kinase (CAMKK,
n= 4); IRA 1 kinase suppressor (IKS, n = 1); numb-associated kinase
(NAK, n= 2); mitotic kinase (NEK, n= 24); PEK (n= 3); polo-like ki-
nase (PLK, n = 1); SCY1 (n = 2); tousled-like kinase (TLK, n = 1);
Unc51-like kinase (ULK, n = 3); VPS15 (n = 1); WEE (n = 2); and
Other-unique (n = 14). Speciﬁc information on each classiﬁed kinase
can be found in Supplementary Table S1 online. Moreover, a phyloge-
netic tree of the L. infantum ePK kinome groups (Fig. 2) was constructed
and representative human kinases of each group were used to root
each tree. The tree was consistent with our classiﬁcations and compar-
ative analysis.
Besides ePKs, 24 protein kinase like (PKL) proteins were identiﬁed,
and were distributed into phosphatidyl-inositol kinase (PIK, n = 5);
phosphatidyl-inositol3 kinase related kinases (PIKK, n = 6); right
open reading frame kinase (RIO, n = 2); ABC1 (n = 5); alpha (n =
4); and CAK (n = 2). We identiﬁed four atypical protein kinases, of
which one was classiﬁed into the A6 family and three were classiﬁed
into the pyruvate dehydrogenase kinase family (PDHK).
We also assessed the transcription proﬁle of L. infantum kinases in
promastigotes. We searched for RNA-seq evidence of the species tran-
scriptome in TriTrypDB [35]. A histogram plot was constructed using
the percentile of expression of each kinome protein in Leishmania
promastigotes (see Supplementary Fig. S1). There are 33 highly expre-
ssed kinases in L. infantumwhich rank at the upper quartile of expres-
sion. At the lower quartile of expression there are 84 kinases. The
other 139 kinases are constitutionally expressed. Most of the highly
expressed kinases are members of the CMGC group, probably due to
the diverse and important functions of MAPK cascades and CDKs [36].
3.1.2. L. braziliensis Kinome
The draft kinome of L. braziliensis contained 195 kinases, 31 of which
could be classiﬁed on the level of subfamilies; 114 on the level of fami-
lies; 22 on the level of groups; and 28 protein kinases remained unclas-
siﬁed. Aftermanual curation (seeMethods), 221 proteins (193 ePKs and
28 PKL/ aPKs)were deﬁned as protein kinases and classiﬁed into groups
(n=3); families (n=61); subfamilies (n=155); and 2 protein kinases
remained unclassiﬁed (Table 1).
A total of 193 ePKs were identiﬁed in the L. braziliensis proteome,
among which there were representatives of 6 kinase groups (Table 2).
The AGC group contained 10 kinases classiﬁed in the following families:
AKT (n= 1); NDR (n= 1); PDK1 (n= 3); PKA (n= 2); and RSK (n=
1). Two AGC kinases were not assigned to any family. The CAMK group
had 23 kinases classiﬁed in the following families: CAMK1 (n = 5);
CAMKL (n= 11); CDPK (n= 2); and CAMK-Unique (n = 5). The CK1
group had 7 kinases classiﬁed into CK1 (n= 6) and TTBK (n= 1) fam-
ilies. There were 49 proteins assigned to the following families of
CMGC group: CDK (n = 12); CK2 (n = 2); CDKL (n = 2); CLK (n =
4); DYRK (n = 9); GSK (n = 2); MAPK (n = 13); RCK (n = 3); and
SRPK (n = 2). Among the STE group, there were 41 kinases classiﬁed
in the following families: STE11 (n = 31); STE20 (n = 2); STE7 (n =
7); and STE-Unique (n = 1). The “Other” group contained 60 kinases
within the following families: AUR (n = 3); Bud32 (n = 1); CAMKK
(n = 4); IKS (n = 1); NAK (n = 2); NEK (n = 23); PEK (n = 3); PLK
(n = 1); SCY1 (n = 2); TLK (n = 1); ULK (n = 3); VPS15 (n = 1);
WEE (n = 1); and Other-Unique (n = 14). One “Other” kinase was
not assigned to any family.
Along with the ePKs, there were 24 PKLs identiﬁed in L. braziliensis
proteome. Theywere classiﬁed in the following families: ABC1 (n=5);
alpha (n= 5); PIK (n= 4); PIKK (n=6); RIO (n= 2); and CAK (n=
2). Therewere also four atypical protein kinases: three PDHKs and one
A6. Since the kinomes L. infantum and L. braziliensis are very similar,
theirphylogenetic treesareverysimilaraswell andthereforewedecided
not to report the tree for L.braziliensis.Speciﬁc informationof eachclassi-
ﬁed kinase can be found at Supplementary Table S2.
3.2. Comparison between L. infantum, L. braziliensis, and Homo sapiens
Kinomes
We compared the kinomes of both Leishmania species and the
human kinome in order to identify candidate drug targets among the
parasites kinome (Fig. 3). The rationale of this approach is that kinases
of both Leishmania species that cluster together and that do not cluster
with human kinasesmay be considered plausible targets. If a compound
inhibits one of these proteins, there is a chance that it can lead to an
Table 2
Kinase's group and family classiﬁcation after curation. The number of proteins in each
group increased after manual curation and almost all were assigned to families; only a
few unclassiﬁed proteins remained in the end of the curation pipeline. Themost represen-
tative groupswere CMGC, STE, and “Other” and the least representative groupswere AGC,
CAMK, and CK1.
Group Family L. infantum L. braziliensis
AGC AKT 1 1
NDR 1 1
PDK1 3 3
PKA 3 2
RSK 2 1
NA⁎ 2 2
Total 12 10
CAMK CAMK1 6 5
CAMKL 11 11
CAMK_Unique 4 5
CDPK 2 2
Total 23 23
CMGC CDK 14 12
CK2 2 2
CDKL 0 2
CLK 4 4
DYRK 9 9
GSK 2 2
MAPK 13 13
RCK 3 3
SRPK 3 2
Total 50 49
CK1 CK1 6 6
TTBK 1 1
Total 7 7
STE STE11 31 31
STE20 2 2
STE7 7 7
STE-Unique 1 1
Total 41 41
Other AUR 3 3
Bud 32 1 1
CAMKK 4 4
IKS 1 1
NAK 2 2
NEK 24 23
PEK 3 3
PLK 1 1
SCY1 2 2
TLK 1 1
ULK 3 3
VPS15 1 1
WEE 2 1
Other-unique 14 14
NA⁎ 0 1
Total 62 61
Unclassiﬁed 1 2
Total epk 196 193
Atypical A6 1 1
PDHK 3 3
Total 4 4
PKL PIK 5 4
PIKK 6 6
RIO 2 2
ABC1 5 5
alpha 4 5
CAK 2 2
Total 24 24
Total PK 224 221
⁎ NA = Not assigned to a family.
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improvement in CL and VL while having less side effects due to off-
target effects. OrthoVenn was used to infer the orthologous clusters
of kinases using the sequences of the proteins from L. infantum,
L. braziliensis, and H. sapiens kinomes. There were 42 clusters of
common orthologous sequences for all three species and 157 clusters
that had only L. infantum and L. braziliensis orthologous sequences.
These 157 clusters were considered for further analysis for target prior-
itization, as they show the least similarity to human kinases.
We conducted a pairwise analysis of the L. infantum and
L. braziliensis kinases with the orthologous kinases of L. major aiming
to compare the similarity between these species kinomes. The
L. major kinome has already been elucidated [21] and our goal was
to understand how similar the orthologous kinases are to both Leish-
mania kinomes, since L. major was used as a reference in one of the
curation steps. The overall range of identity between L. infantum
and L. major proteins was between 83% to 100%, with greater diver-
sity shown between L. braziliensis and L. major proteins, with a
range of identity between 38% to 99%. Kinase groups of both L.
infantum and L. braziliensis demonstrated high similarity to L. major
groups, indicating that the L. major kinome was a good reference to
infer these organisms' kinomes. We compared L. infantum kinome
with L. braziliensis to know if it is possible to extrapolate our target
prioritization approach. The overall range of identity between
L. infantum and L. braziliensis proteins was between 29 and 99%.
When comparing individual groups, thosewith higher shared identi-
ties were AGC, CK1, and CMGC; the “Other” group has the largest
range in identity (29–96%). Likewise, we performed a pairwise
Fig. 2. Phylogenetic analysis of the ePK groups of L. infantum. The catalytic domains of L. infantum ePKswere used to constructML trees using PhyML program. Each of the six kinase groups
is highlighted in a different color and black circles indicate bootstrap support values (1000 replicates) equal or higher than 60%.
Fig. 3. Venn diagram comparing the clusters of orthologous kinases in L. infantum,
L. braziliensis, and H. sapiens. The PKs were grouped in clusters of orthologous sequences
and the groups that shared proteins of the different organisms were partitioned
according to the diagram.
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comparison of Leishmania kinases and H. sapiens homologs [14] that
revealed a lower range of identity: from23 to 69% (L. infantum vH. sa-
piens), and from 21 to 69% (L. braziliensis v H. sapiens). This demon-
strates that Leishmania kinases can be targeted by compounds that
are unlikely to bind human kinases (Table 3 and Supplementary
Table S3).
The 157 Leishmania-speciﬁc protein kinases were then functionally
annotated into 3 levels of KEGG pathways and a pie chart considering
the 2nd level was constructed with 11 functional categories (Fig. 4
and Supplementary Table S3 online). The most represented functions
of kinome proteins were (i) cell growth and death (36%); (ii) signal
transduction (31%); (iii) environmental adaptation (7%); and (iv) me-
tabolism (6%).
3.3. Drug Target Prediction and Repurposing Pipeline
Two bioinformatics approaches were used for target prediction:
(i)protein essentiality and (ii) centrality measures of the kinome
protein-protein interaction graph. For the ﬁrst approach (i), we
used RNAi validations of targets with lethal phenotype in closely re-
lated T. brucei to infer the L. infantum orthologous that are essential
to survival of the parasite. In the second approach, we constructed a
protein interaction network using the kinome proteins as input to
the STRING web server, then using the results in Cytoscape to calcu-
late two network metrics: closeness and betweenness centralities.
These may be considered as proxies for node importance in the in-
teraction network based on their connections to other proteins.
Further, the selected proteins were used to build a sub-network
and the measure of in- and out-degrees was calculated to select
the top connected proteins into the sub-network (Supplementary
Fig. S2). Combining these complementary approaches led to
the prediction of 30 potential new drug targets (Supplementary
Table S4).
Finally, the FASTA sequences of the 30 prioritized targets were used
to interrogate the publicly available databases DrugBank and Kinase
SARfari (Supplementary Fig. S3) in a drug repurposing pipeline. In this
step, the E-value threshold of ≤10−30 was adopted to provide high con-
ﬁdence for the data. This analysis predicted 11 targets associated with
42 drugs (see Supplementary Table S5). These drugs can possibly also
target Leishmania since the sequence conservation between the
human and Leishmania targets is high. Then, we conducted a literature
search of the 42 drugs, in order to check which of them have not been
tested in Leishmania yet. We found that 15 of those drugs have already
been tested in Leishmania, some of them had IC50 lower than 10 μM
[37], demonstrating that our approaches of target selection and drug
repurposing were successful. The 27 compounds that have not been
tested in Leishmania were submitted to an in-house developed QSAR
model for prediction of phenotypic activity against L. infantum. Seven
of them were predicted to be active against L. infantum amastigotes
(Fig. 5). These compounds were then purchased and experimentally
evaluated against L. infantum, L. amazonensis, and L. braziliensis proma-
stigotes and amastigotes.
3.4. Experimental Validation
The kinase inhibitors selumetinib, refametinib, MEK162, MLN-8054,
trametinib, NMS-1286937 and RG-1530 were selected and tested
against L. infantum, L. braziliensis and L. amazonensis promastigotes.
Selumetinib, refametinib, MEK162, MLN-8054 inhibited ~ 70% prom-
astigote growth at concentrations higher than 75 μM, showing poor
leishmanicidal activity. On the other hand, R1530, NMS-1286937 and
Trametinib presented good tomoderate antileishmanial activity against
Leishmania spp. (Table 4).
Cytotoxicity assays showed that RG-1530 was toxic to bone
marrow derived macrophages (BMDM) from BALB/c mice while
NMS-1286937 and Trametinib led to ~15% viability reduction at
50 μM (Supplementary Fig. S4 online). For this reason, the
antileishmanial activity of NMS-1286937 and Trametinib were
evaluated against intracellular amastigotes. NMS-1286937 at 30
μM reduced approximately 50% of L. (L.) infantum parasite burden
whilst Trametinib showed a more pronounced effect at the same
dose (~90% reduction) (Fig. 6). For L. (V.) braziliensis, both
compounds reduced ~50% of intracellular amastigotes at 15 and
30 μM (Fig. 6).
4. Discussion
Our bioinformatics pipeline, expanding on established methods for
kinase identiﬁcation, enabled us to complete the ﬁrst complete deﬁni-
tion and classiﬁcation of the kinomes of two Leishmania species im-
portant to human health. The draft kinome revealed 197 and 195
protein kinases in L. infantum and L. braziliensis, respectively. These
numbers represent 2.35% and 2.08% of these species' genomes. The
curation procedure further improved that number to 224 and 221,
representing 2.67% and 2.35% of their genomes. The number of protein
kinases is compatible with related trypanosomatid kinomes, which
comprise approximately 2% of their genomes [38] and is also compa-
rable to other parasites, such as Plasmodium falciparum (1.5%) [39] and
Schistosoma mansoni (1.9%) [36]. Organisms from the KinBase kinome
database (www.kinase.com), which does not contain trypanosomatid
kinomes, have a similar number of kinases compared with their ge-
nomes ranging from 1.5 to 2% [36].
The large set of PKs in the genus suggests that phosphorylation is
a very important process in parasite biology. There are representa-
tives of six of the nine ePK groups are described by Manning et al.
[14]. Tyrosine Kinase (TK), Tyrosine Kinase Like (TKL), and Receptor
Guanylate Cyclase (RGC) groups are not represented. The phosphor-
ylation of tyrosine residues has been reported in trypanosomatids
[40–43]. This phenomenon was related to the action of atypical tyro-
sine kinases such as Wee1 [44] and dual-speciﬁc protein kinases
such as DYRK, CLK, and STE7. CRK3 may also be involved in tyrosine
phosphorylation since it has a tyrosine residue in a regulatory
subdomain [45].
In comparison with the previously elucidated L. major kinome, the
kinomes of L. infantum and L. braziliensis constituted a larger number
Table 3
Pairwise comparisons of L. infantum kinase sequences with orthologues in L. braziliensis, L. major, and human. BLAST analyses were performed for each sequence in each group. The table
shows the range of identity in the kinase groups between the L. infantum proteins and the organism's proteins listed in each column.
Groups L. infantum x L. braziliensis
identity % range
(mean ± SD)
L. infantum x L. major identity
% range
(mean ± SD)
L. infantum x H. sapiens identity
% range
(mean ± SD)
L. braziliensis x L. major identity
% range
(mean ± SD)
L. braziliensis x H. sapiens
identity % range
(mean ± SD)
AGC 53–96 (81.2 ± 14.9) 82–99 (93.4 ± 5.45) 25–53 (41.58 ± 8.06) 50–93 (78 ± 14.43) 25–53 (37.2 ± 7.74)
CAMK 62–97 (82.7 ± 10.11) 88–100 (94.82 ± 3.34) 23–53 (34.25 ± 7.23) 63–99 (84.39 ± 10.18) 27–69 (41.48 ± 11.19)
CK1 63–98 (80.6 ± 11.02) 90–99 (94.3 ± 3.5) 31–69 (47.7 ± 13.19) 55–95 (72.14 ± 13.88) 23–37 (31.14 ± 4.95)
CMGC 56–99 (83.6 ± 11.0) 84–99 (94.4 ± 4.1) 25–59 (40.66 ± 9.03) 59–97 (82.06 ± 10.04) 28–55 (39.1 ± 7.58)
STE 44–96 (75.5 ± 11.9) 56–99 (90.7 ± 7.69) 23–48 (34.02 ± 5.18) 54–96 (74.95 ± 10.04) 24–48 (34.6 ± 5.76)
Other 29–96 (74.3 ± 14.7) 83–99 (92.38 ± 5.19) 24–67 (34.02 ± 8.16) 38–97 (76.93 ± 12.68) 21–62 (35.29 ± 7.65)
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of proteins (total of 199 protein kinases in L. major kinome) [38]. This
difference may be due to intra-species variability or the more detailed
approach used in the current work. Also, the authors of the L. major
kinome study [21] could only assign the kinases into groups and fami-
lies; our investigation led to a more detailed classiﬁcation and could as-
sign subfamilies to most of proteins.
Fig. 4. Functional annotation of L. infantum and L. braziliensis protein kinase. Protein kinases were distributed into pathways considering KEGG's second level of functional classiﬁcation.
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We aimed to select the proteins with no orthologues in humans,
however, in the target prioritization analysis, half of the selected pro-
teins were clustered with human orthologues. Looking at the sequence
identity of these proteins, we observed that all of them shared b60% of
their identities. It has been shown that kinases with sequence similari-
ties higher than 60% have very similar structures and the compounds
that bind to their sites usually show similar structure-activity-
relationships [13]. Thus, it is possible that the differences in the active
sites of the orthologues can be explored and the binding of off-targets
may be avoided. It also allows for the repurposing of approved drugs.
Our target prioritization approaches enabled us to ﬁnd promising
targets. Eight out of the 33 highly expressed kinases were prioritized
as targets, meaning that our approaches were effective in selecting im-
portant targets. Many of those targets have been genetically validated in
T. brucei, e.g., Aurora kinase 1(AIRK) [46]; Casein kinase 1(CK1) [47];
Cyclin-dependent kinases CRK3 and CRK1 [48]; Glycogen synthase ki-
nase 3(GSK3) [49]; WEE-1 like kinase [44]; and Polo-like kinase (PLK)
[50]. Many of them are also being studied in Leishmania species.
L. major and L. donovani AIRK have been cloned and characterized
[51,52], their cellular locations elucidated during various phases of the
L. donovani cell cycle [52], and chemical validation studies have shown
similar effects compared to the T. brucei validation study [53,54]. CK1
has been identiﬁed as an hexokinase [55] capable of phosphorylating
host proteins [56]. L. major CK1 has been targeted by human casein ki-
nase inhibitors [57] and the kinase has also been chemically validated
in L. donovani [58]. The cyclin-dependent kinases 2 – CRK1 and CRK3
were experimentally validated in L. mexicana as essential proteins [59]
with fundamental roles during cell cycle progression [60]. Also, many
inhibitor-driven studies have been carried in order to reach CRK3 inhi-
bition, but few displayed in vitro activity [61–64]. Recombinant GSK3
was expressed and puriﬁed in L.major and L. infantum. The crystal struc-
ture of LmajGSK3 was elucidated and eleven protein kinase inhibitors
were tested against LinfGSK3, TbruGSK3, and HsapGSK3 enabling a
structure-activity relationship comparison between the binding sites,
which provides ways to predict inhibitors with binding modes that
might be effective and selective [65]. Targeting leishmanial GSK3 led
to cell cycle defects and apoptosis-like death [66]; a study with
indirubin derivatives could enhance the selectivity of the inhibitors to-
wards GSK3 over CRK3 [67]. T. bruceiMKK1 and MKK5 knockout mu-
tants were not essential for the parasite's survival or virulence [68]. In
L. mexicana, MKK1 mutants have a shortened ﬂagellum [69] and
MKK5 activates MPK4, which has been proposed as a drug target [70].
Our drug repurposing approach led to the selection of 7 compounds
with potential as Leishmania inhibitors. Exploration into the biological
targets of parasites with orthologues in mammals has been avoided
for decades, and it aims to eliminate possible problems of selectivity
and adverse effects during the drug development process. However,
the situation is radically different when this parasite protein is
orthologous to a therapeutic drug target. In this case, orthologues can
provide evidence of “druggability” [71]. Three out of seven compounds
were active against L. infantum, L. braziliensis and L. amazonensis
promastigotes. Trametinib was the most potent compound against
L. infantum and L. braziliensis amastigotes. This drug reduced ~50% of in-
tracellular amastigotes at 30 μM for L. infantum and at 15 μM for
L. braziliensis. Trametinib is a drug used for the treatment of anaplastic
thyroid cancer [72]. Its targets are mitogen-activated extracellular
signal-regulated kinase 1 (MEK1 or MAPKK1), MEK2 activation, and
MEK1 andMEK2 kinase activity. MEK proteins are upstream regulators
of the extracellular signal-related kinase (ERK) pathway, which pro-
motes cellular proliferation [73]. The predicted trametinib targets in
Leishmania are also MAPKK1 and MAPKK2. Both share 34% similarity
with human MAPKK1. This reinforces the possibility of repurposing
trametinib to a different application with similar mechanism of action.
NMS-1286937 is an inhibitor of Polo-like kinase 1 (PLK-1), a key com-
ponent of the cell cycle control machinery with important roles in the
mitotic entry, centrosome duplication, bipolar mitotic spindle forma-
tion, transition from metaphase to anaphase, cytokinesis, and mainte-
nance of genomic stability [74]. PLK-1 is also the predicted target of
NMS-1286937 in Leishmania, with 48% of identity. This compound has
good oral bioavailability in rodent and non-rodent species and has
proven antitumor activity in different preclinical models against solid
tumors and hematologic malignancies [75]. R1530 targets known cell
cycle regulators like Aurora Kinase A and PLK4 [76]. R1530 inhibits
tumor growth by blocking a variety of tumorigenic and angiogenic
pathways. This compound did not present any observed toxicity at
doses which resulted in signiﬁcant growth inhibition, tumor regression,
and a signiﬁcant improvement in survival [77]. Although the EC50 of
these compounds were not considered optimal against the Leishmania
species tested (EC50 b 10 μM) [78], here we report only the ﬁrst steps
in a drug discovery pipeline. They might be used as scaffolds for com-
pound optimization and hit selection. Further studies need to be con-
ducted in order to establish in vivo efﬁcacy of kinase inhibitors in
experimental leishmaniasis model.
Table 4
R1530, NMS-1286937 and Trametinib activity against Leishmania spp. promastigotes.
Kinase inhibitor EC50% (μM) [95% CI]
L. (L.) amazonensis RG-1530 61.5 [52.5–70.5]
NMS-1286937 29.9 [26.2–33.6]
Trametinib 23.1 [19.8–26.4]
L. (L.) infantum RG-1530 77.5 [69.7–85.3]
NMS-1286937 13.2 [10.0–16.5]
Trametinib 63.6 [57.8–68.8]
L. (V.) braziliensis RG-1530 62.4 [55.7–69.1]
NMS-1286937 37.3 [31.8–42.8]
Trametinib 68.3 [64.2–72.4]
Fig. 6. Percentage of L. infantum (A) and L. braziliensis (B) intracellular amastigote reduction after incubation with NMS-1286937 (white bars) and Trametinib (black bars) in relation to
control untreated infections (100%).
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In conclusion, the bioinformatics pipeline used in this work allowed
a very thorough classiﬁcation of L. infantum and L. braziliensis kinomes –
most of the kinases were assigned at subfamily level. The functions of
these kinaseswere catalogued and compared to human and other Leish-
mania orthologues. Finally, we predicted 30 protein kinases that have
the potential to be good drug targets. This information will be useful
for the discovery of new leishmanicidal compounds. The drug repurp-
osing pipeline allowed us to ﬁnd a kinase inhibitor currently indicated
for cancer treatments that has the potential to be repositioned for the
treatment of leishmaniasis. The drug trametinib and the compounds
NMS-1286937 and RG-1530 presented good to moderate inhibition of
L. infantum and L. braziliensis amastigotes andmight be used as scaffolds
for future hit-to lead optimization.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.csbj.2019.02.005.
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